<DOC>
	<DOCNO>NCT02048085</DOCNO>
	<brief_summary>This study involve platelet function test patient undergone fibrinolysis . Fibrinolysis ( Use clot bust medicine heart attack ) standard care restore blood flow block artery soon possible `` Heart attack '' rural health center access cardiac catheterization one hour away . Fibrinolysis do emergency room physician timely fashion minimize damage myocardium . Additionally anti-platelet regimen adjuvant patient undergoing fibrinolysis well study many trial . In study investigator use clopidogrel ticagrelor randomize fashion evaluate anti- platelet effect measure efficacy vivo ( pharmacodynamics ) blood level drug ( Pharmacokinetics ) .</brief_summary>
	<brief_title>Comparing Ticagrelor Clopidogrel Pharmacodynamics After Thrombolysis</brief_title>
	<detailed_description>This open label randomize pharmacodynamics study compare platelet function reactivity ticagrelor clopidogrel PCI sub-set patient undergone fibrinolysis least 24 hour prior PCI..A total 70 patient enrol . Prior enrollment , patient already undergone fibrinolysis ( select treat physician ) , aspirin ( recommend dose 324 mg ) first day 81 mg daily thereafter , Lovenox heparin per protocol refer ER . Patients undergo coronary angiography standard care coronary stenting indicate . Prior angiography patient enrol open label randomize protocol receive clopidogrel ticagrelor . Patients randomly assign 1:1 ratio open label study receive either clopidogrel ( Plavix , Sanofi-Aventis Bristol-Myers Squibb ; 300-mg loading dose follow 75 mg daily ) ticagrelor ( Brilinta , AstraZeneca ; 180 mg load 90 mg twice daily ) computerize system randomization . Patients receive clopidogrel ticagrelor daily enrollment discharge . For patient undergo PCI enrollment , study drug administer include day 8th hospital discharge , whichever come first . Patients treat per standard care , pharmacodynamics pharmacokinetic study carry per protocol . VerifyNow VASP assay use measure platelet reactivity pharmacodynamic evaluation ticagrelor v Clopidogrel specific time point : baseline ( time 0 ) , 30 min , 1 hour , 2 hour , 8 hour 24 hour first oral anti-platelet dose.. Blood collect sheath ante-cubital vein Vacutainer tube platelet function assay VerifyNow VASP . VerifyNow P2Y12 Assay : VerifyNow turbidimetric base system measure platelet aggregation whole blood.8 This instrument measure optical signal report P2Y12 Reaction Units ( PRU ) . Vasodilator-Stimulated Phosphoprotein Phosphrylation ( VASP ) Assay : The measure Vasodilator-Stimulated Phosphoprotein Phosphrylation ( Biocytex Inc. Marseille , France ) , method quantify P2Y12 receptor reactivity , reflect extent blockade P2Y12 receptor blockade.9 Platelet reactivity index ( PRI ) calculate measure VASP-P level mean fluorescence intensity ( MFI ) stimulation prostaglandin ; PGE1and PGE1 plus ADP . PRI ( % ) = [ ( MFIPGE1 ) − ( MFIPGE1+ADP ) / ( MFIPGE1 ) ] ×100 % . ) Pharmacokinetic do 30 min , 60 min , 120 min , 4 hour , 8 hour 24 hour . AUC time 0-2 hour , Cmax 2 hour , Tmax 2 hour key secondary endpoint . Will collect Cmax Tmax time point consistent , i.e . 0 , 30 min , 1 hour , 2 hour , 8 hour , 24 hour draw PD measure time point sample ship .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1 . Men woman 18 75 year age 2 . Ischemic discomfort last 20 min rest within 12 hour randomization 3 . STsegment elevation least 0.1 mV least two contiguous limb lead , STsegment elevation least 0.2 mV least two contiguous precordial lead , leave bundlebranch block know old 4 . Received fibrinolytic agent , anticoagulant ( fibrinspecific lytic agent prescribe ) aspirin within 2448 hour 1 . Hypersensitivity ticagrelor clopidogrel 2 . Active Pathological Bleeding history intracranial bleeding 3 . Concomitant use oral anticoagulant 4 . Concomitant use 40 mg Simvastatin lovastatin 5 . Concomitant strong CYP3A inhibitor ketoconazole , clarithromycin , nefazadone , ritonavir , atazanavir 6 . Concomitant use CYP2C19 inhibitor omeprazole esomeprazole 7 . Patients plan urgent CABG 8 . Thrombocytopenia 9 . Dialysis 10 . Use oral antiplatelet agent ( ticagrelor , prasugrel , Clopidogrel ) within 7 day prior enrollment 11 . Use GP IIb/IIIa inhibitor 12 . Rescue PCI ( PCI &lt; 24 hour symptom onset )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>ACS</keyword>
	<keyword>STEMI</keyword>
	<keyword>Fibrinolysis</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Plavix</keyword>
	<keyword>Brilinta</keyword>
	<keyword>Ticagrelor</keyword>
	<keyword>Clopidogrel</keyword>
</DOC>